01—Abstract
Summary
Summary of the 10-Q filed August 6, 2026. Cited figures are marked; the original filing is the authoritative source.
Gilead Sciences, Inc. (GILD) reported a net loss of $10.5 billiona for the three months ended June 30, 2026, a significant shift from the $2.0 billion net income in the prior year period.
This loss was primarily driven by substantial acquired in-process research and development (IPR&D) expenses totaling $11.2 billionb related to key acquisitions, including Arcellx, Tubulis, and Ouro Medicines. Additionally, a $1.75 billion IPR&D impairment charge impacted results. Despite these significant non-recurring charges, total revenues grew by 10% to $7.8 billion, fueled by strong performance in HIV products like Biktarvy and Descovy, alongside growth in Trodelvy and Livdelzi.
The company's balance sheet shows a considerable decrease in cash and cash equivalents, from $7.6 billion at the start of the year to $3.2 billionc, reflecting the significant cash outflows for acquisitions. The substantial investment in R&D and strategic acquisitions highlights Gilead's commitment to expanding its pipeline, particularly in oncology and inflammation, though it has led to a reported net loss for the quarter. Investors should monitor the integration of these acquisitions and the progress of their underlying assets, as well as ongoing litigation risks.
02—Key points
Key Highlights
- Total revenues increased by 10% to $7.8 billion for the three months ended June 30, 2026, compared to $7.1 billion in the prior year, driven by strong HIV product sales and contributions from Trodelvy and Livdelzi.
- Gilead reported a net loss of $10.5 billion for the three months ended June 30, 2026, a significant decline from a net income of $2.0 billion in the same period last year.
- Acquired in-process research and development (IPR&D) expenses were $11.2 billion for the quarter, primarily due to acquisitions of Arcellx, Tubulis, and Ouro Medicines.
- A significant IPR&D impairment charge of $1.75 billion was recorded in the quarter related to the discontinuation of the Trodelvy Phase 3 EVOKE-03 study.
- Cash and cash equivalents decreased significantly to $3.2 billion as of June 30, 2026, from $7.6 billion as of December 31, 2025, reflecting cash used in investing activities for acquisitions.
- HIV product sales showed robust growth, increasing 12% year-over-year for the quarter, led by Biktarvy and Descovy.
- The company is facing ongoing litigation related to antitrust, consumer protection, and product liability, with significant potential financial implications.
03—Questions
Frequently Asked Questions
What caused the significant net loss in the current quarter?
The net loss of $10.5 billion for the three months ended June 30, 2026, was primarily due to substantial acquired in-process research and development (IPR&D) expenses of $11.2 billion, stemming from the acquisitions of Arcellx, Tubulis, and Ouro Medicines. Additionally, a $1.75 billion IPR&D impairment charge related to the discontinuation of the Trodelvy study contributed to the loss.
How did the company's revenue performance compare to the prior year?
Total revenues increased by 10% to $7.8 billion for the three months ended June 30, 2026, compared to $7.1 billion in the same period of 2025. This growth was primarily driven by higher sales of HIV products (Biktarvy and Descovy), Trodelvy, and Livdelzi.
What is the impact of the recent acquisitions on Gilead's financial position?
The recent acquisitions of Arcellx, Tubulis, and Ouro Medicines have significantly impacted the financial position, leading to substantial IPR&D expenses and a reduction in cash and cash equivalents from $7.6 billion at the end of 2025 to $3.2 billion as of June 30, 2026. These investments reflect Gilead's strategic focus on expanding its oncology and inflammation portfolios.
What are the key risks highlighted in the MD&A section?
Key risks highlighted include intense competition in the HIV and oncology markets, pricing and reimbursement pressures from government agencies and payers, potential loss of market exclusivity for key products, ongoing litigation with significant potential financial impact, supply chain and manufacturing risks, and challenges in clinical trial development. The company also notes the impact of evolving laws and regulations, such as the Inflation Reduction Act and potential trade policy changes.
04—Continue